Maccura Biotechnology Co Ltd (300463) — Working Capital to Net Assets Ratio
Maccura Biotechnology Co Ltd (300463) has a Working Capital to Net Assets ratio of 34.6% as of March 2026. Working capital of CN¥2.19 Billion (current assets of CN¥3.20 Billion minus current liabilities of CN¥1.01 Billion) is measured against net assets of CN¥6.31 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Maccura Biotechnology Co Ltd (300463) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Maccura Biotechnology Co Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Maccura Biotechnology Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at 34.6%, reflecting working capital of CN¥2.19 Billion against net assets of CN¥6.31 Billion CNY. Check tangible equity quality of Maccura Biotechnology Co Ltd to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Maccura Biotechnology Co Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Maccura Biotechnology Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Maccura Biotechnology Co Ltd (300463) market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 34.5% | CN¥2.17 Billion | CN¥6.31 Billion | CN¥3.23 Billion | CN¥1.05 Billion | ▼ -3.6 pp |
| 2024 | 38.0% | CN¥2.44 Billion | CN¥6.42 Billion | CN¥3.64 Billion | CN¥1.20 Billion | ▼ -8.9 pp |
| 2023 | 46.9% | CN¥3.10 Billion | CN¥6.61 Billion | CN¥4.22 Billion | CN¥1.12 Billion | ▼ -8.4 pp |
| 2022 | 55.4% | CN¥3.61 Billion | CN¥6.53 Billion | CN¥4.70 Billion | CN¥1.08 Billion | ▼ -0.6 pp |
| 2021 | 56.0% | CN¥2.54 Billion | CN¥4.54 Billion | CN¥3.86 Billion | CN¥1.31 Billion | ▲ +0.4 pp |
| 2020 | 55.6% | CN¥2.23 Billion | CN¥4.01 Billion | CN¥4.03 Billion | CN¥1.80 Billion | ▲ +4.9 pp |
| 2019 | 50.7% | CN¥1.69 Billion | CN¥3.33 Billion | CN¥3.51 Billion | CN¥1.82 Billion | ▼ -4.3 pp |
| 2018 | 55.0% | CN¥1.58 Billion | CN¥2.86 Billion | CN¥2.96 Billion | CN¥1.38 Billion | ▼ -1.9 pp |
| 2017 | 56.9% | CN¥1.49 Billion | CN¥2.61 Billion | CN¥2.32 Billion | CN¥830.62 Million | ▼ -2.5 pp |
| 2016 | 59.5% | CN¥1.36 Billion | CN¥2.28 Billion | CN¥1.75 Billion | CN¥391.20 Million | ▼ -15.0 pp |
| 2015 | 74.5% | CN¥1.49 Billion | CN¥2.00 Billion | CN¥1.78 Billion | CN¥289.75 Million | ▲ +8.4 pp |
| 2014 | 66.1% | CN¥523.58 Million | CN¥792.05 Million | CN¥809.96 Million | CN¥286.38 Million | ▲ +13.7 pp |
| 2013 | 52.4% | CN¥316.65 Million | CN¥604.48 Million | CN¥547.87 Million | CN¥231.21 Million | ▼ -2.6 pp |
| 2012 | 55.0% | CN¥243.54 Million | CN¥442.98 Million | CN¥428.69 Million | CN¥185.15 Million | ▲ +1.3 pp |
| 2011 | 53.7% | CN¥167.37 Million | CN¥311.77 Million | CN¥358.66 Million | CN¥191.29 Million | — |